Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis
暂无分享,去创建一个
Hee-Jin Kim | Kihyun Kim | J. Lee | S. Lim | Soo-Youn Lee | E. Jeon | Jung-Sun Kim | Jung Eun Lee | G. Lee | J. Min | S. Kim | Jin-Oh Choi
[1] M. Dimopoulos,et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.
[2] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Schulman,et al. Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature , 2012, Acta Haematologica.
[4] P. L. Bergsagel,et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. , 2012, Blood.
[5] D. Dingli,et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Hawkins,et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. , 2011, Blood.
[7] M. Skinner,et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. , 2011, Blood.
[8] D. Esseltine,et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. , 2011, Blood.
[9] H. van de Velde,et al. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. , 2011, QJM : monthly journal of the Association of Physicians.
[10] D. Esseltine,et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.
[11] M. Kizaki,et al. Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma. , 2011, Leukemia research.
[12] M. Dimopoulos,et al. A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis , 2010 .
[13] A. Foli,et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. , 2010, Blood.
[14] M. Dimopoulos,et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Abrams,et al. Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity. , 2009 .
[16] D. Reece,et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. , 2009, Blood.
[17] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[18] A. Hacıhanefioğlu,et al. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib , 2008, International journal of hematology.
[19] A. Dispenzieri,et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. , 2008, The New England journal of medicine.
[20] M. Dimopoulos,et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone , 2007, Haematologica.
[21] A. Salvetti,et al. Unexpected cardiotoxicity in haematological bortezomib treated patients , 2007 .
[22] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[23] T. Therneau,et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Merlini,et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. , 2004, Blood.
[25] Giampaolo Merlini,et al. Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.
[26] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[27] R. Fonseca,et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[28] T. Therneau,et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. , 1999, Blood.
[29] Orciuolo Enrico,et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. , 2007, British journal of haematology.
[30] J. Buxbaum,et al. The systemic amyloidoses. , 1998, The New England journal of medicine.
[31] R. Kyle,et al. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.